{"database": "lobbying", "table": "lobbying_activities", "rows": [[3200721, "5d457f88-d852-40d0-b0f8-e72e74c449cc", "Q2", "WHITMER & WORRALL, LLC", 292892, "CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP)", 2024, "second_quarter", "PHA", "Issues related to prescription drug pricing. S. 2305 Biosimilar Red Tape Elimination Act. S. 148 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. S. 1067 Ensuring Timely Access to Generics Act. S. 775/H.R. 3839 Increasing Transparency in Generic Drug Applications Act. S. 1214 Retaining Access and Restoring Exclusivity (RARE) Act.", "HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2024-07-18T16:33:09-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["3200721"], "units": {}, "query_ms": 9.518206003122032, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}